Dr. Eric B. Mann, MD
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- University of Rochester School of Medicine and Dentistry (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 1,277
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: University of Rochester School of Medicine and Dentistry
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
NJ license 25MA07896500
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Eye Associates of North Jersey PA (7 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,277
- Services billed
- 12,472
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient problem focused exam of visual system | 2,040 | 937 |
| Microfluid analysis of tears | 2,030 | 549 |
| Photography of the retina | 1,182 | 936 |
| Established patient complete exam of visual system | 801 | 794 |
| Exam of the internal drainage system of eye | 556 | 548 |
| Imaging of optic nerve | 438 | 421 |
| Exam of visual field with extended testing | 436 | 416 |
| Measurement of nerve conduction using visual stimulation testing with report | 404 | 386 |
| Injection, bimatoprost, intracameral implant, 1 microgram | 370 | 20 |
| Imaging of retina | 227 | 176 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Latanoprost Other prescribers in Dover, NJ | 701 |
| Prednisolone Acetate Other prescribers in Dover, NJ | 439 |
| Lumigan (bimatoprost) Other prescribers in Dover, NJ | 227 |
| Restasis (cyclosporine) Other prescribers in Dover, NJ | 222 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Dover, NJ | 165 |
| Timolol Maleate Other prescribers in Dover, NJ | 143 |
| Tobramycin-Dexamethasone (tobramycin/dexamethasone) Other prescribers in Dover, NJ | 129 |
| Xiidra (lifitegrast) Other prescribers in Dover, NJ | 105 |
| Cyclosporine Other prescribers in Dover, NJ | 88 |
| Rocklatan (netarsudil mesylat/latanoprost) Other prescribers in Dover, NJ | 75 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 282 payments worth $83,383 in total to this clinician.
| Bausch & Lomb Americas Inc. | $38,636 |
|---|---|
| AbbVie Inc. | $21,455 |
| Glaukos Corporation | $14,633 |
| Ocular Therapeutix, Inc. | $2,470 |
| Sun Pharmaceutical Industries Inc. | $1,494 |
| Alcon Vision LLC | $1,065 |
| Mallinckrodt Hospital Products Inc. | $640 |
| Sight Sciences, Inc. | $572 |
| Speaking at a medical education program | $29,175 |
|---|---|
| Consulting Fee | $26,758 |
| Compensation for services other than consulting (speaking, faculty) | $14,840 |
| Food and Beverage | $8,032 |
| Travel and Lodging | $4,478 |
| Education | $99.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Bausch & Lomb Americas Inc. Feb 18, 2025 | Speaking at a medical education program MIEBO; XIIDRA · Ophthalmology | $5,600 |
| Glaukos Corporation May 28, 2025 | Consulting Fee Travoprost Intraocular Implant - iDose · Ophthalmology | $4,800 |
| AbbVie Inc. Sep 25, 2025 | Compensation for services other than consulting (speaking, faculty) DURYSTA · EYE CARE | $4,725 |
| Glaukos Corporation Sep 24, 2025 | Consulting Fee Travoprost Intraocular Implant - iDose · Ophthalmology | $4,625 |
| AbbVie Inc. Mar 31, 2025 | Consulting Fee DURYSTA · EYE CARE | $4,388 |
| AbbVie Inc. Jun 6, 2025 | Compensation for services other than consulting (speaking, faculty) DURYSTA · EYE CARE | $3,375 |
| AbbVie Inc. Nov 19, 2025 | Compensation for services other than consulting (speaking, faculty) DURYSTA · EYE CARE | $3,375 |
| Glaukos Corporation Jun 23, 2025 | Consulting Fee Travoprost Intraocular Implant - iDose · Ophthalmology | $3,000 |
| Bausch & Lomb Americas Inc. Jun 16, 2025 | Speaking at a medical education program MIEBO · Ophthalmology | $2,800 |
| Bausch & Lomb Americas Inc. Mar 12, 2025 | Speaking at a medical education program MIEBO; XIIDRA · Ophthalmology | $2,800 |
All 50 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Bausch & Lomb Americas Inc. Dec 3, 2025 | Speaking at a medical education program MIEBO; XIIDRA · Ophthalmology | $1,400 |
| AbbVie Inc. Nov 19, 2025 | Compensation for services other than consulting (speaking, faculty) DURYSTA · EYE CARE | $3,375 |
| Bausch & Lomb Americas Inc. Nov 13, 2025 | Speaking at a medical education program MIEBO; XIIDRA · Ophthalmology | $2,800 |
| AbbVie Inc. Nov 13, 2025 | Consulting Fee DURYSTA · EYE CARE | $675 |
| Alcon Vision LLC Nov 6, 2025 | Consulting Fee Rocklatan; TRYPTYR · Ophthalmology | $375 |
| Bausch & Lomb Americas Inc. Nov 6, 2025 | Travel and Lodging MIEBO; XIIDRA · Ophthalmology · travel to HOPEWELL JUNCTION, NY | $125 |
| Bausch & Lomb Americas Inc. Nov 5, 2025 | Speaking at a medical education program MIEBO; XIIDRA · Ophthalmology | $2,800 |
| Bausch & Lomb Americas Inc. Oct 29, 2025 | Travel and Lodging MIEBO; XIIDRA · Ophthalmology · travel to EAST STROUDSBURG, PA | $96.60 |
| Bausch & Lomb Americas Inc. Oct 22, 2025 | Speaking at a medical education program MIEBO; XIIDRA · Ophthalmology | $875 |
| Bausch & Lomb Americas Inc. Oct 17, 2025 | Consulting Fee MIEBO; XIIDRA · Ophthalmology | $1,400 |
| Bausch & Lomb Americas Inc. Oct 17, 2025 | Consulting Fee MIEBO; XIIDRA · Ophthalmology | $70.75 |
| AbbVie Inc. Sep 25, 2025 | Compensation for services other than consulting (speaking, faculty) DURYSTA · EYE CARE | $4,725 |
| Glaukos Corporation Sep 24, 2025 | Consulting Fee Travoprost Intraocular Implant - iDose · Ophthalmology | $4,625 |
| AbbVie Inc. Sep 16, 2025 | Travel and Lodging DURYSTA · EYE CARE · travel to ALBANY, NY · in-kind | $850 |
| Mallinckrodt Hospital Products Inc. Aug 28, 2025 | Education ACTHAR · IMMUNOLOGY · in-kind Company’s descriptionRelevant medical textbook or clinical reprint | $99.99 |
| AbbVie Inc. Aug 14, 2025 | Compensation for services other than consulting (speaking, faculty) DURYSTA · EYE CARE | $2,025 |
| Bausch & Lomb Americas Inc. Jul 1, 2025 | Speaking at a medical education program MIEBO; XIIDRA · Ophthalmology | $2,800 |
| Glaukos Corporation Jun 23, 2025 | Consulting Fee Travoprost Intraocular Implant - iDose · Ophthalmology | $3,000 |
| Ocular Therapeutix, Inc. Jun 20, 2025 | Speaking at a medical education program DEXTENZA · Corticosteroid intracanalicular insert | $750 |
| Bausch & Lomb Americas Inc. Jun 16, 2025 | Speaking at a medical education program MIEBO · Ophthalmology | $2,800 |
| Bausch & Lomb Americas Inc. Jun 10, 2025 | Travel and Lodging MIEBO; XIIDRA · Ophthalmology · travel to FAIRFIELD, CT | $126 |
| AbbVie Inc. Jun 6, 2025 | Compensation for services other than consulting (speaking, faculty) DURYSTA · EYE CARE | $3,375 |
| Bausch & Lomb Americas Inc. Jun 5, 2025 | Speaking at a medical education program XIIDRA; MIEBO · Ophthalmology | $250 |
| Bausch & Lomb Americas Inc. Jun 3, 2025 | Travel and Lodging MIEBO · Ophthalmology · travel to PARAMUS, NJ | $199 |
| Bausch & Lomb Americas Inc. Jun 3, 2025 | Travel and Lodging MIEBO · Ophthalmology · travel to PARAMUS, NJ | $195 |
| Glaukos Corporation May 28, 2025 | Consulting Fee Travoprost Intraocular Implant - iDose · Ophthalmology | $4,800 |
| Glaukos Corporation May 28, 2025 | Travel and Lodging Travoprost Intraocular Implant - iDose · Ophthalmology · travel to Los Angeles, CA | $975 |
| AbbVie Inc. May 21, 2025 | Travel and Lodging DURYSTA · EYE CARE · travel to FORT LEE, NJ · in-kind | $53.20 |
| AbbVie Inc. May 21, 2025 | Travel and Lodging DURYSTA · EYE CARE · travel to FORT LEE, NJ · in-kind | $10.00 |
| Bausch & Lomb Americas Inc. May 20, 2025 | Consulting Fee VYZULTA · Ophthalmology | $2,800 |
| Ocular Therapeutix, Inc. May 19, 2025 | Consulting Fee DEXTENZA · Corticosteroid intracanalicular insert | $1,500 |
| Bausch & Lomb Americas Inc. May 19, 2025 | Speaking at a medical education program MIEBO; XIIDRA · Ophthalmology | $700 |
| Bausch & Lomb Americas Inc. May 13, 2025 | Consulting Fee MIEBO; XIIDRA; enVista MX60 IOL · Ophthalmology | $1,750 |
| Sun Pharmaceutical Industries Inc. May 12, 2025 | Compensation for services other than consulting (speaking, faculty) Cequa · Ophthalmology | $1,340 |
| Bausch & Lomb Americas Inc. Apr 28, 2025 | Speaking at a medical education program MIEBO; XIIDRA · Ophthalmology | $2,800 |
| Bausch & Lomb Americas Inc. Apr 21, 2025 | Speaking at a medical education program MIEBO; XIIDRA · Ophthalmology | $2,800 |
| Glaukos Corporation Apr 9, 2025 | Travel and Lodging Travoprost Intraocular Implant - iDose · Ophthalmology · travel to Los Angeles, CA | $386 |
| Bausch & Lomb Americas Inc. Apr 8, 2025 | Consulting Fee | $700 |
| Bausch & Lomb Americas Inc. Apr 3, 2025 | Travel and Lodging MIEBO; XIIDRA · Ophthalmology · travel to YORKTOWN HEIGHTS, NY | $105 |
| Bausch & Lomb Americas Inc. Apr 2, 2025 | Travel and Lodging MIEBO; XIIDRA · Ophthalmology · travel to NEWTOWN, PA | $99.40 |
| AbbVie Inc. Mar 31, 2025 | Consulting Fee DURYSTA · EYE CARE | $4,388 |
| Bausch & Lomb Americas Inc. Mar 12, 2025 | Speaking at a medical education program MIEBO; XIIDRA · Ophthalmology | $2,800 |
| Bausch & Lomb Americas Inc. Feb 18, 2025 | Speaking at a medical education program MIEBO; XIIDRA · Ophthalmology | $5,600 |
| AbbVie Inc. Feb 6, 2025 | Consulting Fee DURYSTA · EYE CARE | $675 |
| Bausch & Lomb Americas Inc. Feb 5, 2025 | Travel and Lodging MIEBO; XIIDRA · Ophthalmology · travel to WEEHAWKEN TOWNSHIP, NJ | $50.40 |
| Bausch & Lomb Americas Inc. Feb 5, 2025 | Travel and Lodging MIEBO; XIIDRA · Ophthalmology · travel to WEEHAWKEN TOWNSHIP, NJ | $10.00 |
| Bausch & Lomb Americas Inc. Feb 4, 2025 | Travel and Lodging MIEBO; XIIDRA · Ophthalmology · travel to MANCHESTER, CT | $981 |
| Bausch & Lomb Americas Inc. Feb 4, 2025 | Travel and Lodging MIEBO; XIIDRA · Ophthalmology · travel to MANCHESTER, CT | $171 |
| Bausch & Lomb Americas Inc. Feb 4, 2025 | Travel and Lodging MIEBO; XIIDRA · Ophthalmology · travel to MANCHESTER, CT | $30.00 |
| Bausch & Lomb Americas Inc. Feb 4, 2025 | Travel and Lodging MIEBO; XIIDRA · Ophthalmology · travel to MANCHESTER, CT | $15.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 5 companies. The companies reported $79,117 in research payments for these studies, mostly to the institutions running them.
- TTAX03-CR010
Biotissue Holdings Inc. - Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
AbbVie Inc. · Completed · NCT03891446 - A Non-interventional, Prospective, Multicenter, Single Arm, Post-Marketing Clinical Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract Extraction
Bausch & Lomb Americas Inc. - A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular…
Astellas Pharma Global Development - A 4-Week, Phase II, Multicenter, Randomized, Double-Masked, Vehicle- Controlled, Parallel Group Study With 4 Weeks of Follow-Up to Evaluate Safety and Efficacy of a new formulation of Recombinant Human Nerve Growth Fa…
Dompe Farmaceutici S.p.a.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.